Latest 3 stories · newest Oct 30, 2026
Acumen Pharmaceuticals reported that sabirnetug failed to meet its primary cognitive endpoint in a Phase 2 trial for Alzheimer's disease, leading the company to halt development of the drug and focus on strategic options and cash conservation.
Acumen Pharmaceuticals expects to report topline results for its Alzheimer's drug Phase 2 trial in November 2026 and currently has $78.6 million in cash. The CEO highlighted continued progress on a new brain delivery franchise.
Acumen Pharmaceuticals nominated ACU301 and ACU401 as development candidates combining its amyloid beta oligomer antibodies with JCR Pharmaceuticals' blood-brain barrier penetration technology. The company plans to submit an IND application in mid-2027, expanding its pipeline with a differentiated b…
The same ABOS feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ABOS/newsSTART FREE